MedTrace Logo

Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA

NCT04264767 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2022-06-08

No results posted yet for this study

Summary

Nucleix EpiCheck® tests analyzes the methylation pattern in a panel of DNA methylation biomarkers and determines whether this pattern is consistent with cancer under test or with non-cancer tissue.

This study is being performed as part of the development process of the Pan Cancer EpiCheck test which includes the identification of different methylation profiles in various cancer types and healthy controls.

Conditions

Interventions

PROCEDURE

Blood collection

Peripheral blood collection via routine venipuncture

Sponsors & Collaborators

  • Nucleix Ltd.

    lead INDUSTRY

Principal Investigators

  • Shmulik Adler · Nucleix Ltd.

Eligibility

Min Age
22 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-17
Primary Completion
2021-01-30
Completion
2021-01-30

Countries

  • United States
  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04264767 on ClinicalTrials.gov